Promising New Treatment for Metastatic Breast Cancer

At the European Society for Medical Oncology (ESMO) 2023 Congress Aditya Bardia, MD, MPH, presented results from the TROPION-Breast01 trial, which is comparing a new antibody-drug conjugate, datopotamab-deruxtecan (dato-DXd), to doctors’ choice of chemotherapy for inoperable or metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown while being treated with hormonal therapy and also had been treated with chemotherapy. Listen to the podcast to hear Dr. Bardia explain: what an antibody-drug conjugate is the design of the TROPION-Breast01 study and the first results dato-DXd side effects how dato-DXd might fit into the current treatment landscape for metastatic breast cancer

Om Podcasten

Breastcancer.org is a nonprofit organization dedicated to providing the most reliable, complete, and up-to-date information about breast cancer. Our mission is to help women and their loved ones make sense of the complex medical and personal information about breast cancer, so they can make the best decisions for their lives. Breastcancer.org podcasts offer unique insights on prevention, treatment, research, and other breast cancer topics from our medical experts and invited guests.